vs
Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $66.0M, roughly 1.1× SOLENO THERAPEUTICS INC). SOLENO THERAPEUTICS INC produced more free cash flow last quarter ($43.5M vs $14.4M).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
PBYI vs SLNO — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.5M | $66.0M |
| Net Profit | — | $26.0M |
| Gross Margin | 69.3% | 98.3% |
| Operating Margin | 22.7% | 33.5% |
| Net Margin | — | 39.4% |
| Revenue YoY | 27.7% | — |
| Net Profit YoY | — | 134.0% |
| EPS (diluted) | $0.26 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.5M | — | ||
| Q3 25 | $54.5M | $66.0M | ||
| Q2 25 | $52.4M | $32.7M | ||
| Q1 25 | $46.0M | — | ||
| Q4 24 | $59.1M | — | ||
| Q3 24 | $80.5M | — | ||
| Q2 24 | $47.1M | — | ||
| Q1 24 | $43.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | $8.8M | $26.0M | ||
| Q2 25 | $5.9M | $-4.7M | ||
| Q1 25 | $3.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $20.3M | — | ||
| Q2 24 | $-4.5M | — | ||
| Q1 24 | $-4.8M | — |
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | 98.3% | ||
| Q2 25 | 76.5% | 97.9% | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
| Q4 25 | 22.7% | — | ||
| Q3 25 | 17.6% | 33.5% | ||
| Q2 25 | 12.7% | -20.0% | ||
| Q1 25 | 8.7% | — | ||
| Q4 24 | 22.6% | — | ||
| Q3 24 | 27.4% | — | ||
| Q2 24 | -4.6% | — | ||
| Q1 24 | -5.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | 16.2% | 39.4% | ||
| Q2 25 | 11.2% | -14.4% | ||
| Q1 25 | 6.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | -9.6% | — | ||
| Q1 24 | -11.0% | — |
| Q4 25 | $0.26 | — | ||
| Q3 25 | $0.17 | $0.47 | ||
| Q2 25 | $0.12 | $-0.09 | ||
| Q1 25 | $0.06 | — | ||
| Q4 24 | $0.40 | — | ||
| Q3 24 | $0.41 | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $97.5M | $498.9M |
| Total DebtLower is stronger | $22.7M | — |
| Stockholders' EquityBook value | $130.3M | $494.8M |
| Total Assets | $216.3M | $599.9M |
| Debt / EquityLower = less leverage | 0.17× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $97.5M | — | ||
| Q3 25 | $94.4M | $498.9M | ||
| Q2 25 | $96.0M | $286.8M | ||
| Q1 25 | $93.2M | — | ||
| Q4 24 | $101.0M | — | ||
| Q3 24 | $96.7M | — | ||
| Q2 24 | $96.8M | — | ||
| Q1 24 | $107.2M | — |
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
| Q4 25 | $130.3M | — | ||
| Q3 25 | $115.3M | $494.8M | ||
| Q2 25 | $104.7M | $240.1M | ||
| Q1 25 | $97.1M | — | ||
| Q4 24 | $92.1M | — | ||
| Q3 24 | $71.1M | — | ||
| Q2 24 | $48.5M | — | ||
| Q1 24 | $51.0M | — |
| Q4 25 | $216.3M | — | ||
| Q3 25 | $202.9M | $599.9M | ||
| Q2 25 | $194.9M | $332.3M | ||
| Q1 25 | $196.2M | — | ||
| Q4 24 | $213.3M | — | ||
| Q3 24 | $220.7M | — | ||
| Q2 24 | $205.0M | — | ||
| Q1 24 | $214.1M | — |
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.4M | $43.5M |
| Free Cash FlowOCF − Capex | $14.4M | $43.5M |
| FCF MarginFCF / Revenue | 19.1% | 65.8% |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | $41.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | $43.5M | ||
| Q2 25 | $14.1M | $-12.6M | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | $11.2M | — |
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | $43.5M | ||
| Q2 25 | $14.1M | $-12.6M | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | — | — |
| Q4 25 | 19.1% | — | ||
| Q3 25 | 17.7% | 65.8% | ||
| Q2 25 | 26.8% | -38.6% | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.10× | 1.67× | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
